Cutia Therapeutics (HK:2487) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cutia Therapeutics’ CEO and Executive Director, Ms. Zhang Lele, demonstrated her confidence in the company by purchasing 8,000 additional shares with her personal funds, signaling potential growth and stability to shareholders and investors. The company has assured that it maintains the required public float in compliance with Hong Kong’s listing rules, post-purchase. Shareholders are cautioned to exercise prudence when dealing in company shares.
For further insights into HK:2487 stock, check out TipRanks’ Stock Analysis page.